title: Fructose-1,6-bisphosphate has anticonvulsant activity in models of acute seizures in adult rats.
abstract: A variety of observations suggest that decreasing glycolysis and increasing levels of reduced glutathione, generated by metabolism of glucose through the pentose phosphate pathway, would have an anticonvulsant effect. Because fructose-1,6-bisphosphate (F1,6BP) shifts the metabolism of glucose from glycolysis to the pentose phosphate pathway, it was hypothesized to have anticonvulsant activity. The anticonvulsant activity of F1,6BP was determined in rat models of acute seizures induced by pilocarpine, kainic acid, or pentylenetetrazole. The efficacy of F1,6BP was compared with that of 2-deoxyglucose (2-DG; an inhibitor of glucose uptake and glycolysis), valproic acid (VPA), and the ketogenic diet. One hour before each convulsant, Sprague Dawley rats received either saline (as seizure controls), F1,6BP (0.25, 0.5 or 1 g/kg), 2-DG (0.25 or 0.5 g/kg), or VPA (0.3 g/kg). Additional animals received the ketogenic diet (starting at 20 or 60 d old). Time to seizure onset, seizure duration, and seizure score were measured in each group. F1,6BP had dose-dependent anticonvulsant activity in all three models, whereas VPA had partial efficacy. 2-DG was only effective in the pilocarpine model. The ketogenic diet had no effect in these models. F1,6BP was also partially effective when given at the first behavioral seizure after pilocarpine. Administration of sodium lactate, which bypasses the block in the glycolytic pathway, abolished the anticonvulsant activity of 2-DG in the pilocarpine model, but only decreased the efficacy of F1,6BP. These data demonstrate that F1,6BP has significant anticonvulsant efficacy.
authors.affiliation: Department of Pharmacology, Baylor College of Medicine, Houston, Texas 77030, USA.
authors.forename: Xiao-Yuan
authors.initials: XY
authors.lastname: Lian
authors.forename: Firdous A
authors.initials: FA
authors.lastname: Khan
authors.forename: Janet L
authors.initials: JL
authors.lastname: Stringer
mesh_terms: D000208:Acute Disease; D000499:Allylamine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000704:Analysis of Variance; D000818:Animals; D000927:Anticonvulsants / Q000627:therapeutic use*; D001522:Behavior, Animal / Q000187:drug effects; D003847:Deoxyglucose / Q000008:administration & dosage; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D005635:Fructosediphosphates / Q000627:therapeutic use*; D007608:Kainic Acid; D008297:Male; D008614:Meperidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D008956:Models, Chemical; D010862:Pilocarpine; D051381:Rats; D017207:Rats, Sprague-Dawley; D012640:Seizures / Q000139:chemically induced / Q000517:prevention & control*; D014635:Valproic Acid / Q000627:therapeutic use
chemical_list: D000927:Anticonvulsants; D004338:Drug Combinations; D005635:Fructosediphosphates; D010862:Pilocarpine; D000499:Allylamine; D014635:Valproic Acid; C010597:ketobemidone, N,N-dimethyl-3,3-diphenyl-1-methylallylamine drug combination; D008614:Meperidine; D003847:Deoxyglucose; C029063:fructose-1,6-diphosphate; D007608:Kainic Acid